- Home
- RNXT vs LITS Comparison
RNXT vs LITS Comparison
Compare RNXT & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNXT | LITS |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.4M | 40.8M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | RNXT | LITS |
|---|---|---|
| Price | $0.80 | $1.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | 200.6K | ★ 338.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.60 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,000.00 | N/A |
| Revenue This Year | $2,995.35 | N/A |
| Revenue Next Year | $219.61 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.70 | $0.95 |
| 52 Week High | $1.45 | $3.03 |
Technical Indicators
Market Signals| Indicator | RNXT | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 35.98 | 52.29 |
| Support Level | $0.70 | $1.17 |
| Resistance Level | $1.07 | $1.65 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 13.46 | 83.91 |
Price Performance
Historical ComparisonAbout RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.